Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semi-allogeneic fibroblasts
- Development stage
- Discontinued
- Lead developer
- University of Pittsburgh
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Intradermal
01
Overview
A personalized cancer vaccine platform consisting of semi-allogeneic fibroblasts transfected with autologous tumor-derived DNA. The fibroblasts serve as a vehicle to express and present tumor-associated antigens (TAAs) to the patient's immune system. The vaccine is lethally irradiated before administration to ensure safety while maintaining immunogenicity. This approach aims to induce a systemic, tumor-specific T-cell response, particularly in patients with non-small cell lung cancer (NSCLC). The development of this specific vaccine for NSCLC was conducted at the University of Pittsburgh, though the primary clinical trial was terminated.
- Other names
- semi-allogeneic fibroblasts transfected with autologous tumor-derived DNADNA-transfected human allogeneic fibroblastsautologous tumor DNA-transfected semi-allogeneic fibroblasts
Beyond the preview
Go deeper on semi-allogeneic fibroblasts.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semi-allogeneic fibroblasts.